Next Article in Journal
Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt’s Lymphoma
Next Article in Special Issue
Administration of Bacterial Lipopolysaccharide during Early Postnatal Ontogenesis Induces Transient Impairment of Long-Term Synaptic Plasticity Associated with Behavioral Abnormalities in Young Rats
Previous Article in Journal
Acknowledgement to Reviewers of Pharmaceuticals in 2019
Previous Article in Special Issue
ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma

Current Trends in the Pharmacotherapy of Cataracts

Department of Pharmacology & Neuroscience, School of Medicine, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA
Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA
College of Southern Nevada, Las Vegas, NV 89146, USA
Department of Biology/Microbiology/Biotechnology, Federal University Ndufu Alike Ikwo, Abakaliki, Nigeria
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(1), 15;
Received: 19 December 2019 / Revised: 9 January 2020 / Accepted: 10 January 2020 / Published: 16 January 2020
(This article belongs to the Special Issue Choices of the Journal)
Cataracts, one of the leading causes of preventable blindness worldwide, refers to lens degradation that is characterized by clouding, with consequent blurry vision. As life expectancies improve, the number of people affected with cataracts is predicted to increase worldwide, especially in low-income nations with limited access to surgery. Although cataract surgery is considered safe, it is associated with some complications such as retinal detachment, warranting a search for cheap, pharmacological alternatives to the management of this ocular disease. The lens is richly endowed with a complex system of non-enzymatic and enzymatic antioxidants which scavenge reactive oxygen species to preserve lens proteins. Depletion and/or failure in this primary antioxidant defense system contributes to the damage observed in lenticular molecules and their repair mechanisms, ultimately causing cataracts. Several attempts have been made to counteract experimentally induced cataract using in vitro, ex vivo, and in vivo techniques. The majority of the anti-cataract compounds tested, including plant extracts and naturally-occurring compounds, lies in their antioxidant and/or free radical scavenging and/or anti-inflammatory propensity. In addition to providing an overview of the pathophysiology of cataracts, this review focuses on the role of various categories of natural and synthetic compounds on experimentally-induced cataracts. View Full-Text
Keywords: cataracts; lens; lens transparency; lens opacification; lens crystallins; antioxidants; glutathione; superoxide dismutase cataracts; lens; lens transparency; lens opacification; lens crystallins; antioxidants; glutathione; superoxide dismutase
Show Figures

Figure 1

MDPI and ACS Style

Heruye, S.H.; Maffofou Nkenyi, L.N.; Singh, N.U.; Yalzadeh, D.; Ngele, K.K.; Njie-Mbye, Y.-F.; Ohia, S.E.; Opere, C.A. Current Trends in the Pharmacotherapy of Cataracts. Pharmaceuticals 2020, 13, 15.

AMA Style

Heruye SH, Maffofou Nkenyi LN, Singh NU, Yalzadeh D, Ngele KK, Njie-Mbye Y-F, Ohia SE, Opere CA. Current Trends in the Pharmacotherapy of Cataracts. Pharmaceuticals. 2020; 13(1):15.

Chicago/Turabian Style

Heruye, Segewkal H., Leonce N. Maffofou Nkenyi, Neetu U. Singh, Dariush Yalzadeh, Kalu K. Ngele, Ya-Fatou Njie-Mbye, Sunny E. Ohia, and Catherine A. Opere. 2020. "Current Trends in the Pharmacotherapy of Cataracts" Pharmaceuticals 13, no. 1: 15.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop